94 related articles for article (PubMed ID: 700357)
21. The effects of psychotomimetics and psychomotor stimulants on two schedules promoting response switching in the rat.
Evenden J
Psychopharmacology (Berl); 2002 Oct; 163(3-4):381-90. PubMed ID: 12373438
[TBL] [Abstract][Full Text] [Related]
22. [Studies on the effect of certain neurohormones and psychotropic drugs on bioelectric activity of the central nervous system and behavior in ants (Formica rufa L.)].
Kostowski W; Beck J; Meszaros J
Acta Physiol Pol; 1966; 17(1):119-33. PubMed ID: 5917788
[No Abstract] [Full Text] [Related]
23. An animal behavior model for decreased central serotonergic function.
Jacobs BL; Trulson ME
Adv Exp Med Biol; 1981; 133():657-80. PubMed ID: 7315613
[No Abstract] [Full Text] [Related]
24. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
Marona-Lewicka D; Thisted RA; Nichols DE
Psychopharmacology (Berl); 2005 Jul; 180(3):427-35. PubMed ID: 15723230
[TBL] [Abstract][Full Text] [Related]
25. Ontogeny of the behavioral effects of lysergic acid diethylamide in cats.
Trulson ME; Howell GA
Dev Psychobiol; 1984 Jul; 17(4):329-46. PubMed ID: 6745496
[TBL] [Abstract][Full Text] [Related]
26. Dissociations between the effects of hallucinogens on behavior and raphe unit activity in behaving cats.
Trulson ME
Pharmacol Biochem Behav; 1986 Feb; 24(2):351-7. PubMed ID: 3952126
[TBL] [Abstract][Full Text] [Related]
27. Maternal-fetal transfer of abused substances: pharmacokinetic and pharmacodynamic data.
Lee CC; Chiang CN
NIDA Res Monogr; 1985; 60():110-47. PubMed ID: 2997613
[No Abstract] [Full Text] [Related]
28. Delta 9-tetrahydrocannabinol produced discrimination in pigeons.
Henriksson BG; Johansson JO; Järbe TU
Pharmacol Biochem Behav; 1975; 3(5):771-4. PubMed ID: 1208619
[TBL] [Abstract][Full Text] [Related]
29. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex.
Gresch PJ; Smith RL; Barrett RJ; Sanders-Bush E
Neuropsychopharmacology; 2005 Sep; 30(9):1693-702. PubMed ID: 15756304
[TBL] [Abstract][Full Text] [Related]
30. [Effects of D-lysergic acid diethylamide (LSD-25) and 2-bromo-D-lysergic acid diethylamide (BOL-148) on sleeping behavior in rats].
Loew DM; Depoortere H; Vigouret JM
Naunyn Schmiedebergs Arch Pharmakol; 1970; 266(4):394-5. PubMed ID: 4326420
[No Abstract] [Full Text] [Related]
31. Lysergic acid diethylamide causes photoreceptor cell damage through inducing inflammatory response and oxidative stress.
Hu QD; Xu LL; Gong Y; Wu GH; Wang YW; Wu SJ; Zhang Z; Mao W; Zhou YS; Li QB; Yuan JS
Cutan Ocul Toxicol; 2018 Sep; 37(3):233-239. PubMed ID: 29298533
[TBL] [Abstract][Full Text] [Related]
32. A comparative behavioral study of ditran and LSD in mice, rats, and dogs.
Cohen M; Wakeley H
Arch Int Pharmacodyn Ther; 1968 Jun; 173(2):316-26. PubMed ID: 5684262
[No Abstract] [Full Text] [Related]
33. LSD acts synergistically with serotonin depletion: evidence from behavioral studies in cats.
Trulson ME; Jacobs BL
Pharmacol Biochem Behav; 1976 Mar; 4(3):231-4. PubMed ID: 132670
[TBL] [Abstract][Full Text] [Related]
34. Single dose and cross tolerance studies of beta-phenethylamine, d-amphetamine and LSD in the chronic spinal dog.
Vaupel DB; Nozaki M; Martin WR; Bright LD
Eur J Pharmacol; 1978 Apr; 48(4):431-7. PubMed ID: 648586
[TBL] [Abstract][Full Text] [Related]
35. 'Candyflipping': synergistic discriminative effect of LSD and MDMA.
Schechter MD
Eur J Pharmacol; 1998 Jan; 341(2-3):131-4. PubMed ID: 9543229
[TBL] [Abstract][Full Text] [Related]
36. Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and delta 9-THC, using the micronucleus test.
Van Went GF
Experientia; 1978 Mar; 34(3):324-5. PubMed ID: 631257
[TBL] [Abstract][Full Text] [Related]
37. The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle.
Geyer MA; Petersen LR; Rose GJ; Horwitt DD; Light RK; Adams LM; Zook JA; Hawkins RL; Mandell AJ
J Pharmacol Exp Ther; 1978 Dec; 207(3):837-47. PubMed ID: 731434
[TBL] [Abstract][Full Text] [Related]
38. EEG effects of hallucinogens and cannabinoids using sleep-waking behavior as baseline.
Fairchild MD; Jenden DJ; Mickey MR; Yale C
Pharmacol Biochem Behav; 1980 Jan; 12(1):99-105. PubMed ID: 6102770
[TBL] [Abstract][Full Text] [Related]
39. On the specificity of a cat behavior model for the study of hallucinogens.
Marini JL; Sheard MH
Eur J Pharmacol; 1981 Apr; 70(4):479-87. PubMed ID: 7238573
[TBL] [Abstract][Full Text] [Related]
40. Complications associated with lysergic acid diethylamide (LSD-25).
COHEN S; DITMAN KS
JAMA; 1962 Jul; 181():161-2. PubMed ID: 13880315
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
